Pfizer-Olema Collaboration Targets Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) is among the undervalued wide moat stocks to buy now. Olema Pharmaceuticals has announced its collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in the treatment of metastatic breast cancer. Under the clinical trial partnership, both companies will examine the palazestrant-atirmociclib combination in approximately 35 patients, anticipated to begin in H2 2025.

With Olema leading the study, Pfizer Inc. (NYSE:PFE) will serve as the supplier of atirmociclib for use in the Phase 1b/2. As stated by Sean P. Bohen, the President and Chief Executive Officer of Olema Oncology,

“We are excited to assess this combination in the clinic as we seek to establish palazestrant as a potential backbone endocrine therapy for metastatic breast cancer.”

Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability

Known to everyone since the COVID days, Pfizer Inc. (NYSE:PFE) has demonstrated a performance that is nothing short of excellence. From richer profit margins and expanding cash flows to an overall improved balance sheet, the company has showcased financial resilience. With that being said, new acquisitions and partnerships are just the cherry on top, supporting the giant’s 2030 growth outlook.

Pfizer Inc. (NYSE:PFE) is a New York-based biopharmaceutical company that develops and sells medicines and vaccines in several therapeutic areas. Founded in 1849, the company is committed to breakthroughs that transform people’s lives.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.